198 related articles for article (PubMed ID: 22985069)
1. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.
Meng F; Hou J; Shao YX; Wu PY; Huang M; Zhu X; Cai Y; Li Z; Xu J; Liu P; Luo HB; Wan Y; Ke H
J Med Chem; 2012 Oct; 55(19):8549-58. PubMed ID: 22985069
[TBL] [Abstract][Full Text] [Related]
2. Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.
Wang H; Luo X; Ye M; Hou J; Robinson H; Ke H
J Med Chem; 2010 Feb; 53(4):1726-31. PubMed ID: 20121115
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Shao YX; Huang M; Cui W; Feng LJ; Wu Y; Cai Y; Li Z; Zhu X; Liu P; Wan Y; Ke H; Luo HB
J Med Chem; 2014 Dec; 57(24):10304-13. PubMed ID: 25432025
[TBL] [Abstract][Full Text] [Related]
4. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
5. Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems.
Sivakumar D; Mudedla S; Jang S; Kim H; Park H; Choi Y; Oh J; Wu S
Biomolecules; 2021 May; 11(5):. PubMed ID: 34068780
[TBL] [Abstract][Full Text] [Related]
6. Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.
Huang M; Shao Y; Hou J; Cui W; Liang B; Huang Y; Li Z; Wu Y; Zhu X; Liu P; Wan Y; Ke H; Luo HB
Mol Pharmacol; 2015 Nov; 88(5):836-45. PubMed ID: 26316540
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
[TBL] [Abstract][Full Text] [Related]
9. Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach.
Hassaan EA; Sigler SC; Ibrahim TM; Lee KJ; Cichon LK; Gary BD; Canzoneri JC; Piazza GA; Abadi AH
Med Chem; 2016; 12(5):472-7. PubMed ID: 26648332
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Singh N; Patra S
Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
Huai Q; Wang H; Zhang W; Colman RW; Robinson H; Ke H
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9624-9. PubMed ID: 15210993
[TBL] [Abstract][Full Text] [Related]
12. Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.
Hou J; Xu J; Liu M; Zhao R; Luo HB; Ke H
PLoS One; 2011 Mar; 6(3):e18092. PubMed ID: 21483814
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
[TBL] [Abstract][Full Text] [Related]
14. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
Huai Q; Wang H; Sun Y; Kim HY; Liu Y; Ke H
Structure; 2003 Jul; 11(7):865-73. PubMed ID: 12842049
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.
Wu Y; Wang Q; Jiang MY; Huang YY; Zhu Z; Han C; Tian YJ; Zhang B; Luo HB
J Med Chem; 2021 Jul; 64(13):9537-9549. PubMed ID: 34142552
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
Su T; Zhang T; Xie S; Yan J; Wu Y; Li X; Huang L; Luo HB
Sci Rep; 2016 Feb; 6():21826. PubMed ID: 26911795
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
Lee ME; Markowitz J; Lee JO; Lee H
FEBS Lett; 2002 Oct; 530(1-3):53-8. PubMed ID: 12387865
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors.
El-Sharkawy LY; El-Sakhawy RA; Abdel-Halim M; Lee K; Piazza GA; Ducho C; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2018 May; 351(5):e1800018. PubMed ID: 29656464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
